Pub Date : 1999-05-01DOI: 10.1046/J.1525-1411.1999.09923.X
Ken‐ryu Han, A. Pantuck, N. Lobby, J. Marmar
{"title":"Signet Ring Cell Carcinoma of the Prostate: Case Report and Review of the Literature","authors":"Ken‐ryu Han, A. Pantuck, N. Lobby, J. Marmar","doi":"10.1046/J.1525-1411.1999.09923.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09923.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"55 1","pages":"144-145"},"PeriodicalIF":0.0,"publicationDate":"1999-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84715706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-05-01DOI: 10.1046/J.1525-1411.1999.09928.X
H. Grönberg
{"title":"Prostate Cancer Susceptibility Genes: A Current Update","authors":"H. Grönberg","doi":"10.1046/J.1525-1411.1999.09928.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09928.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"7 10 1","pages":"115-119"},"PeriodicalIF":0.0,"publicationDate":"1999-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88617243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-05-01DOI: 10.1046/J.1525-1411.1999.09920.X
S. Sundararaman, D. Nori, S. Parikh, J. Moni, A. Osian, C. Wilson
Brachytherapy is an excellent definitive treatment modality for select patients with localized prostate cancer. Sixty-four patients with Stage T2a prostate adenocarcinoma were identified from the series of prostate patients receiving conformal outpatient brachytherapy between 1990 and 1997. Pretreatment Gleason scores and prostate specific antigen (PSA) values ranged from 2 to 10 and 1.5 to 100, respectively. Median follow-up was 48.5 months. The 5-year overall survival rate was 82.5%, whereas the cause-specific survival rate was 93.7%. The biochemical freedom-from-relapse (bFFR), defined as a PSA level of ≤ 1.0 for patients presenting with Gleason scores of ≤ 5, was 68%; 80% with Gleason scores of ≤ 5 and presenting PSA levels of ≤ 10. In patients with Gleason scores of 6 at presentation, the overall bFFrR was 67%; 87% with a Gleason scores of 6 and PSA levels of ≤ 10. The bFFR was maintained in more than half of patients with Gleason scores of 7 only if they presented with PSA levels of ≤ 10. All patients who presented with PSA levels of ≤ 10 had bFFRs of 75%, compared to 36% for those patients presenting with PSA levels of > 10. These data show that patients with Gleason scores of ≤ 5 can achieve very good PSA control with brachytherapy, especially if the presenting PSA level is ≤ 10. Consideration of PSA is of greater import when a Gleason score ≥ 6 is encountered at presentation. Our data show that durable bFFR can be achieved in patients presenting with Stage T2a disease, Gleason scores of 5–7, and PSA levels of ≤ 10. These results need to be confirmed with further follow-up and other prospective data.
{"title":"Extended Follow-Up of Patients with Stage T2a Prostate Adenocarcinoma After Outpatient Conformal Brachytherapy: Risk Stratification for Treatment Optimization","authors":"S. Sundararaman, D. Nori, S. Parikh, J. Moni, A. Osian, C. Wilson","doi":"10.1046/J.1525-1411.1999.09920.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09920.X","url":null,"abstract":"Brachytherapy is an excellent definitive treatment modality for select patients with localized prostate cancer. Sixty-four patients with Stage T2a prostate adenocarcinoma were identified from the series of prostate patients receiving conformal outpatient brachytherapy between 1990 and 1997. Pretreatment Gleason scores and prostate specific antigen (PSA) values ranged from 2 to 10 and 1.5 to 100, respectively. Median follow-up was 48.5 months. The 5-year overall survival rate was 82.5%, whereas the cause-specific survival rate was 93.7%. The biochemical freedom-from-relapse (bFFR), defined as a PSA level of ≤ 1.0 for patients presenting with Gleason scores of ≤ 5, was 68%; 80% with Gleason scores of ≤ 5 and presenting PSA levels of ≤ 10. In patients with Gleason scores of 6 at presentation, the overall bFFrR was 67%; 87% with a Gleason scores of 6 and PSA levels of ≤ 10. The bFFR was maintained in more than half of patients with Gleason scores of 7 only if they presented with PSA levels of ≤ 10. All patients who presented with PSA levels of ≤ 10 had bFFRs of 75%, compared to 36% for those patients presenting with PSA levels of > 10. These data show that patients with Gleason scores of ≤ 5 can achieve very good PSA control with brachytherapy, especially if the presenting PSA level is ≤ 10. Consideration of PSA is of greater import when a Gleason score ≥ 6 is encountered at presentation. Our data show that durable bFFR can be achieved in patients presenting with Stage T2a disease, Gleason scores of 5–7, and PSA levels of ≤ 10. These results need to be confirmed with further follow-up and other prospective data.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"50 1","pages":"131-137"},"PeriodicalIF":0.0,"publicationDate":"1999-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80961948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-05-01DOI: 10.1046/J.1525-1411.1999.09929.X
R. S. Gould
A comparison of prostate specific antigen (PSA) levels at 1 year after cryosurgery is made for three groups of patients: those who underwent standard cryosurgery with the use of a 37°C urethral warmer, those who underwent cryosurgery with the use of a 22°C warmer, and those who underwent cryosurgery with no warmer used. Those patients who underwent standard cryosurgery were further divided into those who had less aggressive disease (by determination of pretreatment PSA level and tumor grade) and those with more aggressive disease. No significant difference was found in the results of treatment by varying the urethral warming temperature. Aggressive tumors did not respond well to standard cryosurgery. Complete ablation of the prostate by freezing without the use of a warming catheter, however, dramatically improved treatment results. Further studies are thereby felt to be warranted.
{"title":"Variations in Urethral Warming Temperatures During Cryosurgery: The Impact On Post‐Treatment PSA Levels","authors":"R. S. Gould","doi":"10.1046/J.1525-1411.1999.09929.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09929.X","url":null,"abstract":"A comparison of prostate specific antigen (PSA) levels at 1 year after cryosurgery is made for three groups of patients: those who underwent standard cryosurgery with the use of a 37°C urethral warmer, those who underwent cryosurgery with the use of a 22°C warmer, and those who underwent cryosurgery with no warmer used. Those patients who underwent standard cryosurgery were further divided into those who had less aggressive disease (by determination of pretreatment PSA level and tumor grade) and those with more aggressive disease. No significant difference was found in the results of treatment by varying the urethral warming temperature. Aggressive tumors did not respond well to standard cryosurgery. Complete ablation of the prostate by freezing without the use of a warming catheter, however, dramatically improved treatment results. Further studies are thereby felt to be warranted.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"16 9 1","pages":"146-149"},"PeriodicalIF":0.0,"publicationDate":"1999-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87358245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09918.X
N. Kyprianou
{"title":"Induction of Prostate Apoptosis in Response to α1-Adrenoceptor Antagonists: Therapeutic Significance in Benign Prostatic Hyperplasia and Prostate Cancer","authors":"N. Kyprianou","doi":"10.1046/J.1525-1411.1999.09918.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09918.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"76 1","pages":"73-81"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84051972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09915.X
M. Collins, K. Kleinman, M. Barry, J. Meigs, S. Yurgalevitch, J. Mckinlay
Background: To determine whether six lifestyle factors (dietary fat, smoking, sleep, alcohol consumption, physical, and sexual activities) are associated with non-prostate cancer-related, elevated prostate specific antigen (PSA) levels. Methods: PSA levels were measured on frozen serum that was collected at baseline (time T1, 1987–1989) and at follow-up (time T2, 1995–1996) in the Massachusetts Male Aging Study, a population-based random sample survey of 1709 men aged 39–70 years old. Men with a PSA level >4.0 ng/ml at time T2 were offered a biopsy. Excluding men who had ever had a diagnosis of prostate cancer (N = 82) left 892 men with both time T1 and time T2 PSA measurements. Lifestyle factors assessed at time T1 were used for the analysis. Results: Of 866 men who had a time T1 PSA 4.0 ng/ml at time T2. In logistic regression models predicting crossing the threshold of 4.0 ng/ml, sexual activity was a significant predictor, but other lifestyle factors were not. Relative to little or no sexual activity, the age-adjusted odds ratio for sex 1–3 times/month was 4.18 (95% confidence interval (CI) = 1.4–12.3), and for sex ≥4 times/month was 2.54 (95% CI = 0.9–6.9). Conclusions: Men who were more sexually active at time T1 were at higher risk of a falsely elevated PSA level >4.0 ng/ml at time T2. Although interim knowledge about lifestyle is lacking, this finding may reflect the effect of ejaculation on serum PSA. Other lifestyle factors had no effect on time T2 PSA levels.
{"title":"Prostate Specific Antigen Levels: Effect of Sexual Activity","authors":"M. Collins, K. Kleinman, M. Barry, J. Meigs, S. Yurgalevitch, J. Mckinlay","doi":"10.1046/J.1525-1411.1999.09915.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09915.X","url":null,"abstract":"Background: To determine whether six lifestyle factors (dietary fat, smoking, sleep, alcohol consumption, physical, and sexual activities) are associated with non-prostate cancer-related, elevated prostate specific antigen (PSA) levels. \u0000 \u0000Methods: PSA levels were measured on frozen serum that was collected at baseline (time T1, 1987–1989) and at follow-up (time T2, 1995–1996) in the Massachusetts Male Aging Study, a population-based random sample survey of 1709 men aged 39–70 years old. Men with a PSA level >4.0 ng/ml at time T2 were offered a biopsy. Excluding men who had ever had a diagnosis of prostate cancer (N = 82) left 892 men with both time T1 and time T2 PSA measurements. Lifestyle factors assessed at time T1 were used for the analysis. \u0000 \u0000Results: Of 866 men who had a time T1 PSA 4.0 ng/ml at time T2. In logistic regression models predicting crossing the threshold of 4.0 ng/ml, sexual activity was a significant predictor, but other lifestyle factors were not. Relative to little or no sexual activity, the age-adjusted odds ratio for sex 1–3 times/month was 4.18 (95% confidence interval (CI) = 1.4–12.3), and for sex ≥4 times/month was 2.54 (95% CI = 0.9–6.9). \u0000 \u0000Conclusions: Men who were more sexually active at time T1 were at higher risk of a falsely elevated PSA level >4.0 ng/ml at time T2. Although interim knowledge about lifestyle is lacking, this finding may reflect the effect of ejaculation on serum PSA. Other lifestyle factors had no effect on time T2 PSA levels.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"42 1","pages":"82-87"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86887300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09917.X
J. Zacks, S. Brecher
{"title":"Acute and Chronic Prostatitis Syndromes: A Review of Microbiologic and Pathologic Issues","authors":"J. Zacks, S. Brecher","doi":"10.1046/J.1525-1411.1999.09917.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09917.X","url":null,"abstract":"","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"1 1","pages":"68-72"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83023505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09911.X
C. Naughton, W. Tourtellotte, Deborah S. Smith, J. Milbrandt
Objective: Nerve growth factor-induced gene A (NGFIA) is a transcription factor implicated in androgen deprivation-induced apoptosis in an androgen-sensitive prostate cell line ( 1, 2). The objective of our study was to investigate the role of NGFIA in prostate apoptosis in response to androgen ablation in a mouse animal model lacking the gene. Materials and Methods: Wild-type mice (n = 56) and NGFIA-deficient mice (“knock-out”) (n = 16) were surgically castrated. The animals were killed at 0 (noncastrated controls), 1, 3, 5, 7, 10, 14, and 21 days after castration, and the prostates were harvested. Tissue sections were stained for morphologic analysis and quantification of apoptosis using a terminal deoxynucleotidyl transferase biotinylated deoxyuridine triphosphate nick-end labeling (TUNEL) strategy. Apoptosis was quantitatively measured by counting the number of TUNEL-positive cells/100 epithelial cells by light microscopy. The percentage of apoptosis was compared for wild-type mice versus NGFIA-deficient mice after castration at the defined time points. Results: We found a statistically significant increase in the mean percentage of prostate cell apoptosis within 7–21 days after castration in both wild-type and NGFIA-deficient mice (p 0.05). Conclusion: NGFIA does not seem to play a critical role in prostate apoptosis induced by androgen ablation in this mouse model.
{"title":"Prostate Apoptosis in Response to Castration in Wild‐Type and Nerve Growth Factor‐Induced Gene A‐Deficient Mice","authors":"C. Naughton, W. Tourtellotte, Deborah S. Smith, J. Milbrandt","doi":"10.1046/J.1525-1411.1999.09911.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09911.X","url":null,"abstract":"Objective: Nerve growth factor-induced gene A (NGFIA) is a transcription factor implicated in androgen deprivation-induced apoptosis in an androgen-sensitive prostate cell line ( 1, 2). The objective of our study was to investigate the role of NGFIA in prostate apoptosis in response to androgen ablation in a mouse animal model lacking the gene. \u0000 \u0000 \u0000 \u0000Materials and Methods: Wild-type mice (n = 56) and NGFIA-deficient mice (“knock-out”) (n = 16) were surgically castrated. The animals were killed at 0 (noncastrated controls), 1, 3, 5, 7, 10, 14, and 21 days after castration, and the prostates were harvested. Tissue sections were stained for morphologic analysis and quantification of apoptosis using a terminal deoxynucleotidyl transferase biotinylated deoxyuridine triphosphate nick-end labeling (TUNEL) strategy. Apoptosis was quantitatively measured by counting the number of TUNEL-positive cells/100 epithelial cells by light microscopy. The percentage of apoptosis was compared for wild-type mice versus NGFIA-deficient mice after castration at the defined time points. \u0000 \u0000 \u0000 \u0000Results: We found a statistically significant increase in the mean percentage of prostate cell apoptosis within 7–21 days after castration in both wild-type and NGFIA-deficient mice (p 0.05). \u0000 \u0000 \u0000 \u0000Conclusion: NGFIA does not seem to play a critical role in prostate apoptosis induced by androgen ablation in this mouse model.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"9 1","pages":"88-92"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85006971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09919.X
K. Alexandrou, G. N. Collins, Alison Wynn-Davies, P. O’Reilly
Introduction: The degree of increase in prostate specific antigen (PSA) forms after prostatic manipulation may differ depending on histology. We sought to critically evaluate this hypothesis and to examine possible clinical implications. Methods: A series of 198 men referred for transrectal ultrasound-guided biopsy on clinical grounds had free (fPSA) and total PSA (tPSA) levels determined before undergoing biopsy and 30 min after biopsy. A subset of 100 men had the same analysis immediately before and 30 min after digital rectal examination (DRE). Geometric mean ratios and two-sample t tests compared the change in levels of fPSA, PSA, the ratio of fPSA to tPSA (f/t PSA), fPSA density, and PSA density after manipulation to prostatic histology. Results: After undergoing biopsies, 57 men (29%) received a diagnosis of prostate cancer. The biopsy significantly altered all parameters. The degree of change was less in the malignant group for all parameters, although this only approached statistical significance for PSA and PSA density levles (p = 0.159 and p = 0.170, respectively). In the DRE group, the PSA changes were similar, although the cancer patients tended to release slightly less PSA forms (PSA, p = 0.376; fPSA, p = 0.657; f/t PSA, p = 0.396). Conclusion: PSA release and PSA parameter alteration after manipulation differ in the neoplastic prostate. The subtlety of change after DRE currently limits clinical application.
前列腺操作后前列腺特异性抗原(PSA)形式的增加程度可能因组织学而异。我们试图批判性地评估这一假设，并检查可能的临床意义。方法:198例经直肠超声引导活检的男性患者在活检前和活检后30分钟分别测定游离PSA (fPSA)和总PSA (tPSA)水平。100名男性的一个子集在直肠指检(DRE)之前和之后30分钟进行了相同的分析。几何平均比和双样本t检验比较操作后fPSA水平、PSA、fPSA / tPSA之比(f/t PSA)、fPSA密度和PSA密度对前列腺组织学的变化。结果:接受活检后，57名男性(29%)被诊断为前列腺癌。活检明显改变了所有参数。在所有参数中，恶性组的变化程度较小，尽管这仅在PSA和PSA密度水平上接近统计学意义(p = 0.159和p = 0.170)。在DRE组中，PSA变化相似，尽管癌症患者倾向于释放略少的PSA形式(PSA, p = 0.376;fPSA, p = 0.657;f/t PSA, p = 0.396)。结论:在肿瘤前列腺中，手法治疗后PSA释放及PSA参数改变存在差异。DRE术后变化的微妙性目前限制了临床应用。
{"title":"A Critical Evaluation of Prostate Specific Antigen Parameter Responses to Manipulation According to Prostatic Histology","authors":"K. Alexandrou, G. N. Collins, Alison Wynn-Davies, P. O’Reilly","doi":"10.1046/J.1525-1411.1999.09919.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09919.X","url":null,"abstract":"Introduction: The degree of increase in prostate specific antigen (PSA) forms after prostatic manipulation may differ depending on histology. We sought to critically evaluate this hypothesis and to examine possible clinical implications. \u0000 \u0000 \u0000 \u0000Methods: A series of 198 men referred for transrectal ultrasound-guided biopsy on clinical grounds had free (fPSA) and total PSA (tPSA) levels determined before undergoing biopsy and 30 min after biopsy. A subset of 100 men had the same analysis immediately before and 30 min after digital rectal examination (DRE). Geometric mean ratios and two-sample t tests compared the change in levels of fPSA, PSA, the ratio of fPSA to tPSA (f/t PSA), fPSA density, and PSA density after manipulation to prostatic histology. \u0000 \u0000 \u0000 \u0000Results: After undergoing biopsies, 57 men (29%) received a diagnosis of prostate cancer. The biopsy significantly altered all parameters. The degree of change was less in the malignant group for all parameters, although this only approached statistical significance for PSA and PSA density levles (p = 0.159 and p = 0.170, respectively). In the DRE group, the PSA changes were similar, although the cancer patients tended to release slightly less PSA forms (PSA, p = 0.376; fPSA, p = 0.657; f/t PSA, p = 0.396). \u0000 \u0000 \u0000 \u0000Conclusion: PSA release and PSA parameter alteration after manipulation differ in the neoplastic prostate. The subtlety of change after DRE currently limits clinical application.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"135 1","pages":"93-98"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76904120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-03-01DOI: 10.1046/J.1525-1411.1999.09912.X
E. Reed, Douglas J Matthews, V. Dyer, W. Figg
Leptomeningeal involvement of metastatic prostate cancer is a rare clinical entity. We report such a case, along with a summary of three previous cases where detailed clinical information is available. Seven additional cases (for a total of 10 cases) have been reported previously in the literature. It seems that this syndrome is associated with changes in mentation, specifically without cranial nerve findings on physical exam. The physician should be alerted to the possibility of this clinical circumstance in metastatic prostate cancer patients with altered mental status.
{"title":"Meningeal Carcinomatosis in Metastatic Prostate Cancer: A Case Report","authors":"E. Reed, Douglas J Matthews, V. Dyer, W. Figg","doi":"10.1046/J.1525-1411.1999.09912.X","DOIUrl":"https://doi.org/10.1046/J.1525-1411.1999.09912.X","url":null,"abstract":"Leptomeningeal involvement of metastatic prostate cancer is a rare clinical entity. We report such a case, along with a summary of three previous cases where detailed clinical information is available. Seven additional cases (for a total of 10 cases) have been reported previously in the literature. It seems that this syndrome is associated with changes in mentation, specifically without cranial nerve findings on physical exam. The physician should be alerted to the possibility of this clinical circumstance in metastatic prostate cancer patients with altered mental status.","PeriodicalId":22947,"journal":{"name":"The open prostate cancer journal","volume":"83 1","pages":"99-102"},"PeriodicalIF":0.0,"publicationDate":"1999-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75918575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：